Cosentyx begins competition in the market

Benefit applied with primary biological sanctions from August and entered simultaneously with Taltz.

Extensive symptom improvement advantages and ease of dosage adjustment with effectiveness

Compete with Taltz

As Interleukin-17 (IL-17) sanctions enter the primary biological formulation benefit range for psoriasis arthritis, they will compete in earnest with TNF-α inhibitors.

 

Cosentyx (Secukinumab) of Novartis expanded health insurance benefits from psoriasis arthritis to primary biological sanctions on the 1st.

 

Cosentyx can be used if it meets certain conditions among active and progressive arthritis patients who are not effective in treating two or more types of DMARDs or who are difficult to treat due to side effects.

 

The condition is for patients with three or more compressed joints and three or more edema joints.

 

Previously, IL-17 regulations were paid only when TNF-α inhibitors were used first and used as secondary biological regulations in patients with insufficient response or difficulty in treatment due to side effects.

 

This expansion allows Cosentyx to be prescribed in a position equivalent to the TNF-α regulation.

 

Of course, it is not easy to compete with TNF-α drugs, which have long been widely used for autoimmune diseases such as psoriasis arthritis.

 

In response, the interleukin formulation was intended to demonstrate superiority with head-to-head clinical trials.

 

EXCEED studies, phase 3 clinical trial of Cosentyx, are typical.

 

The effectiveness and safety of Cosentyx was compared as a control group with the representative TNF-α formulation, Humira (Adalimumab).

 

The main evaluation item is ACA20 at week 52 of treatment, which represents a 20% improvement in arthritis.

 

Clinical results show that the Cosentyx group and the Adalimumab group had a 67% to 62% ACR20 ratio, which resulted in Cosentyx absolute value, but did not satisfy statistical significance (p=0.0719).

 

However, the rate of improvement in Psoriasis symptoms (PASI 90), a secondary evaluation variable, was significantly different from 65% to 43%.

 

We also demonstrated significant improvements in the integrated evaluation variables ACR50 (more than 50% improvement in arthritis) and PASI100 indicators by 31% versus 19%.

 

The percentage of patients who maintained treatment until the 52nd week was 86% to 76%, which was higher in Cosentyx.

 

Shin Ki-chul, a professor of rheumatology at Boramae Hospital, said at a Cosentyx conference on the 25th, "Although ACR20 did not satisfy the statistical significance, it was different in ACR50 and it was more effective in ACR70.

 

Of course, the primary indicator was set to ACR20 and the clinical design." The advantage of Cosentyx, which differentiates itself from conventional TNF formulations, is that it comprehensively treats the major symptoms of psoriasis arthritis.

 

Cosentyx may be a priority consideration, especially in patients with spondylitis.

 

International treatment guidelines have also changed accordingly.

 

GRAPPA (Psoriasis and Psoriasis Arthritis Research and Assessment Group), a renowned international research group, recommends Cosentyx as a primary biological agent in the treatment of psoriasis arthritis, skin psoriasis, hand and toe psoriasis.

 

The EULAR also suggested Cosentyx as the primary biological agent in arthritis and spinal arthritis in late 2019 and stated that it could be preferred over TNF inhibitors when there are related skin symptoms such as psoriasis.

 

"The fact that IL-17 inhibitors are more effective in skin psoriasis than TNF preparations is now somewhat established.

 

In addition, Cosentyx has the advantage of being able to control the dose from 150mg to 300mg.

 

"It is reasonable to consider Cosentyx as the primary biological agent for psoriasis and other symptoms such as psoriasis." Competition with Taltz, which entered the primary benefit range at the same time, is also noteworthy.

 

Paul Thomas, a medical director at Novartis Korea, said, "The study confirmed that Cosentyx is less likely to develop immunogenicity." Humanized antibodies are those that increase the similarity to human antibodies.

 

Furthermore, human antibodies have no animal-derived parts, minimizing immunogenicity.

 

Cosentyx is also attempting to enter primary biological sanctions in ankylosing spondylitis.

 

Park Hye-yoon, executive director of the Novartis Transplant Immunity and Skin Disease Division, said, "We are trying to deliver good news in Korea as Cosentyx is being paid in most major countries such as the U.S., Canada, Japan and Australia under the primary regulation of ankylosing spondylitis."